Gilead has exclusive rights for the advancement and commercialization of anti-IL18 binding protein antibodies targeting various tumor types. Gilead commits to a significant deal, including a €55 million ($60 million) upfront payment and a €27 million ($30 million) milestone payment in the near term, with a total potential value of up to €775 million ($848 million).
